The new version of DaraEx can be ordered for validation purposes under the article number 004 020 001 with the remark "lot P22I18-004" or "new DaraEx version with purple lid". In approximately three months the new version of DaraEx will replace the old version.
The new version of DaraEx (=RUO) is also available as the CE-IVD marked product DaraEx plus with the article number 004 020 004. Please note that the process control for these products has an adjusted protein concentration and is available under the new product name "Dara-PC" with the article number 004 020 005.
Further information is provided here.
DaraEx - anti-CD38 antibody neutralizing agent
Antibody based drugs can disturb serological blood group testing since the examined antigens can be masked by the therapeutic antibodies. An anti-CD38 antibody for treatment of multiple myeloma shows a strong interference in the indirect antiglobulin test (IAT) where most of the reactions turn to unspecifically (wrong) positive. The time consuming standard technique using Dithiothreitol (DTT) counteracts the interference but has major drawbacks like destruction of Kel antigens or hemolysis. The imusyn DaraEx compound inhibits the agglutination effect of anti-CD38 in IAT without side effects.
Method
- Preincubation of test cells with DaraEx for 30 min
- Cells can be used for indirect antiglobulin test with conventional gel card systems
Advantages of DaraEx
- Quick and simple procedure
- Specific inhibition of anti-CD38 reactivity without affecting other antigens or alloantibody reactions
- No side effects like destruction of blood group antigens or hemolysis as described for the standard DTT treatment
- No need for expensive anti-idiotypic antibodies or soluble CD38 protein for blocking anti-CD38
| Art. No. | Name | Description |
|---|---|---|
| RUO | Not for use in diagnostic procedures - USA and Canada | |
| 004 020 001 | DaraEx | Tube á 300µl |
| 004 020 002 | DaraEx Positive Control, 450µl |
Improved DaraEx version is now available as RUO and CE-IVD
We are happy to announce that the anti-CD38 antibody neutralizing agent DaraEx has now an improved functionality by changing the chemistry from a F(ab)2 fragment to a Fab fragment. The new uniform express protocol does not need a pre-incubation of the test cells with DaraEx anymore. Instead DaraEx can be added directly on the gel card without any delay in the indirect antiglobulin test (IAT).
| Art. No. | Name | Description |
|---|---|---|
| RUO | Not for use in diagnostic procedures - USA and Canada | |
| 004 020 001 NEW | DaraEx RUO version | Tube á 300µl |
| 004 020 004 | DaraEx plus CE-IVD | Tube á 300µl |
| 004 020 005 | Dara-PC | Tube á 450µl |
Contact Form
Call
+49 (0) 6173 607930
Call from USA/Canada
+1 (888) 352 2196